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Brucellosis exists worldwide.The disease mainly spreads by ingestion of unpasteurized dairy products. It is a systemic 
disease, and many systems can be involved. The clinical presentation may be acute or insidious. The disease mimics 
many illnesses and presents diagnostic difficulties. Automated blood culture systems, PCR and ELISA have proved 
useful as new laboratory-based diagnostic methods. Although various regimens have been used in the treatment of 
the disease, a combination of doxycycline and streptomycin seems to be the best current treatment for human 
brucellosis. 
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Brucellosis is a zoonotic disease of worldwide distribu- 
tion and still remains endemic in some developing 
countries. It affects mainly domestic animals, producing 
genitourinary infections leading to abortions. The illness 
continues to be one of the most widely distributed 
zoonoses, causing devastating economic losses, and 
commonly affects humans. Q Human brucellosis has a 
wide clinical spectrum, and presents various diagnostic 
difficulties because it mimics many other diseases. There 
is still no optimal therapy for some particular clinical 
forms of brucellosis and there are difficulties with pre- 
ventive measures in developing countries. The perspec- 
tive of this article will be particularly on the clinical and 
therapeutic features of human brucellosis. 
The disease, as a debilitating illness characterized 
by malaise, anorexia, fever, and profound muscular 
weakness, was described by Marston in 1860. The 
responsible microorganism was isolated by David Bruce 
in 1887. Since then, new species have been identified. At 
present, there are six known species of brucellae, 
including B. melitensis, B. abortus, B. suis, B. canis, B. ovis, 
and B. neotomae. A distinctive Brucella strain recently 
isolated was given the tentative name Brucella maris. 
Brucella species are gram-negative coccobacillary, 
nonmotile, aerobic microorganisms. The cells do not 
produce capsules, spores, or flagella. They do not grow 
well on media commonly used in microbiology labora- 
tories, Growth is best on trypticase soy agar, Brucella 
agar or serum dextrose agar at 37%!, especially if a 
biphasic culture system is used. B. abortus and B. suis 
require supplementary CO2 for growth, especially for 
primary isolation. This conventional culture method 
requires prolonged incubation (up to 3 weeks) and the 
use of blind subcultures.3 Currently available methods 
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that have been advocated include lysis-centrifugation 
(Isolator) blood cultures and the use of automated, 
continuous-monitoring blood culture instrument- 
ation.3-5 
EPIDEMIOLOGY 
Brucella spp. can infect many species of animals and 
humans. Domestic animals serve as the reservoir. The 
host range for Brucella spp. is shown in Table 1. The main 
pathogenic species worldwide are B. abortus, responsible 
for bovine brucellosis, B. melitensis, the main etiologic 
agent of ovine and caprine brucellosis, and B. suis, which 
has a wide host range, not being confined to swine, and all 
strains of which are human pathogens, except for biovar 
2. These three Brucella spp. usually cause abortion in their 
natural hosts, resulting in huge economic losses. They also 
account for most cases of human brucellosis. B. melitensis 
is the most virulent species. B. canis is occasionally 
involved in human diseases. B. maris has been isolated 
from marine mammals.1~3~6,7 Only two cases of human 
infection with a marine isolate have been reported.8 
Diseased animals excrete Brucella through the 
urine, milk, placenta and the products of miscarriages. In 
this way, the bacteria are disseminated and infect other 
animals and humans. The survival of Brucella outside 
the animal organism is variable. The duration of survival 
of Brucella in moist soil, in dung spread on the ground, 
has been reported to be 70-80 days. The survival of B. 
melitensis in dust varies from 15 to 40 days, depending 
on the ambient humidity.2 Consequently, brucellosis is 
an occupational risk for farmers, veterinarians, abattoir 
workers and laboratory personnel.6z7;9 
The main sources of Brucella are infected animals 
or their products, such as milk, cream, butter, fresh 
cheese, ice cream, urine, blood, carcasses, and abortion 
products. Routes .of transmission of the infection to 
humans include direct contact with infected animals and 
their secretions through cuts and abrasions in the skin, 
by way of infected aerosols inhaled or inoculated into 
the conjunctival sac of the eyes, or via the ingestion of 
unpasteurized dairy products.1~2Jj~7~g 
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Table 1. Species of Bruce//a and animal reservoirs 
Species Reservoir Other hosts Human cases 
(worldwide) 
B. melitensis 
B. abortus 
B. suis 
B. ovis 
B. canis 
B. neotomae 
B. maris 
Goat, sheep, camel 
Cattle, buffalo, yaks, bison 
Swine 
Sheep 
Dog 
Desert wood rat 
Marine mammals 
Cattle, antelope 
Horse 
Cattle, caribou 
++++ (70% of cases) 
+++ (25% of cases) 
++ (5% of cases) 
No 
Few 
No 
No 
Milk is the main food product serving as a vector for 
Brucelh The consumption of fresh, raw milk from 
animals is traditional, particularly in Saudi Arabia and 
other Arabic countries, which have a high incidence of 
brucellosis.9 Different kinds of fresh cheese are certainly 
the foodstuffs responsible for human brucellosis, 
especially goat and ewe cheeses. Brucdu in cheeses 
preserved in paste form survives, on average, for 20 days, 
and sometimes up to 3 months. Meat products are rarely 
the source of infection, because they are not usually 
eaten raw and the numbers of organisms in muscle 
tissue are 10w.~,~ The control of animal brucellosis is very 
important for the prevention of human infection. Also 
important in the prevention of human infection is the 
use of pasteurized milk and milk products in developing 
countries. 
Laboratory workers handling Bruceh cultures have 
a high risk of acquiring brucellosis through accidents, 
aerosols, or inadequate laboratory precautions.9J0 In our 
experience, veterinarians may also be infected by 
accidental inoculation percutaneously or into the 
conjunctival sac with live B. abortus strain 19 vaccine. 
Human brucellosis can occur in any age group, but 
the majority of cases are found in young men between 
the ages of 20 and 40 years. This is generally related to 
occupational hazards in young men.7,11-14 All persons 
having an underlying disease-HIV infection, chronic 
renal disease or liver disease-living in endemic areas 
have the same risk as healthy people of acquiring 
brucellosis.15-l7 
Human-to-human transmission is unusual. How- 
ever, rare cases due to blood transfusion, bone marrow 
transplantation and sexual transmission have been 
reported.18-21 
The true incidence of human brucellosis is unknown. 
The World Health Organization (WHO) points out that 
500 000 cases of brucellosis are reported each year from 
around the world. The reported incidence and 
prevalence of the disease vary widely from country to 
country. B. abortus is more prevalent in the USA and 
northern Europe, whereas B. melitensis is more common 
in Latin America, the Mediterranean countries, and the 
developing countries. Some areas, such as Peru, Kuwait, 
and Saudi Arabia, are hyper-endemic for Brucella 
infection. The re-emergence of brucellosis in Malta and 
Oman has been reported. ls5s9 Turkey is also an endemic 
country for brucellosis. In 1999, 11 462 cases were 
notified to the Ministry of Health, with the incidence 
rate being 17.41/100 000. The distribution of cases of 
human brucellosis reported between 1970 and 1999 is 
shown in Figure 1. 22 In a multicenter seroprevalence 
study in Turkey, the seropositivity rate was found to be 
1.8% in the healthy population and 6% in high-risk 
occupational groups (veterinarians, workers in abattoirs, 
butchers, etc.). 23 The seropositivity rate for brucellosis in 
a seroprevalence study from Saudi Arabia was reported 
to be 15%.9 In the USA, as an example of a developed 
country, brucellosis is seen sporadically, and occurred in 
the Mexican border region at a rate eight times the 
national rate (0.18/100 000 in the Mexican border 
region versus 0.09/100 000 and 0.02/100 000 nationally). 
The epidemiology has also changed in this border 
region, from an occupational disease associated with 
animal contact to a foodborne disease associated with 
consumption of unpasteurized dairy products.24 
PATHOGENESIS 
Brucellu spp. are pathogenic bacteria of humans and 
animals, and are exceedingly well adapted to their hosts. 
They are facultative intracellular pathogens, surviving 
and multiplying within cells of the reticuloendothelial 
system and not surviving for long periods of time in 
open conditions. The bacteria can enter the body by 
ingestion, inhalation, penetration of intact skin, 
abrasions, or the conjunctival mucosa.1-3,6,7,9 The low pH 
of gastric juice provides some protection against oral 
infection. Antacids or H2 receptor blockers may increase 
susceptibility to brucellosis. 25 Normal human serum has 
moderate anti-Brucellu activity, and complement opso- 
nizes organisms for phagocytosis. Human neutrophils 
destroy some Brucellu strains, but they lack activity 
against B. melitensis.26,27 
Virulent Brucella organisms can infect both non- 
phagocytic and phagocytic cells. The intracellular 
environment of host cells sustains extensive reproduc- 
tion, allowing bacterial expansion and subsequent trans- 
mission to new host cells. In contrast to other pathogenic 
bacteria, no classical virulence factors have been 
described’in Brucella organisms. Instead of these, some 
molecular determinants are described for Brucella spp. 
as virulence elements, allowing them to invade, resist 
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Figure 1. The distribution of human brucellosis recorded by the Ministry of Health of Turkey between 1970 and 1999. 
intracellular killing, and reach their reproductive niche 
in professional or non-professional phagocytes.** 
Once BruceZZu invades the mucosa, professional 
phagocytes lying underneath the submucosa ingest the 
bacterium. Macrophages and neutrophils ingest Brucella 
by zipper-like phagocytosis. Opsonized Brucella organ- 
isms are internalized via complement and Fc receptors 
in macrophages and monocytes,28,29 whereas non- 
opsonized Brucella organisms enter via lipid rafts.30,31 
Activation of small GTPases of the Rho subfamily, such 
as Rho, Rat, and Cdc42, is required for Brucella inter- 
nalization in non-professional phagocytes.28,29 
Invasion of cells by BruceZZa is inhibited by chemicals 
and toxins that increase the level of cyclic AMP l(dibutyl- 
CAMP and Vibrio cholerue enterotoxin), but it is stimul- 
ated by toxins and chemicals that increase the levels of 
CAMP (Escherichia coli enterotoxin A and dibutyl- 
cGMP). This suggests an inverse relationship between 
these two secondary messengers during Brucella 
infection.28 
Rough BruceZZu attaches in higher numbers to cells 
than does smooth Brucella, although the former is less 
efficient at invading cells than the latter. This pheno- 
menon suggests that 0-polysaccharide and the structur- 
ally related native hapten have a role in the invasion of 
cells by BruceZZa and in virulence. Recently, a regulatory 
two-component system (BruceZZa virulence-related 
regulator or sensor proteins-BvrR/BvrS) has been 
described as playing a role in host cell invasion.28,32 
Once virulent Brucella is ingested, the bacterium 
redirects its intracellular trafficking through a unique 
pathway until reaching its place of reproduction. Phago- 
cytes are generally prone to kill the ingested BruceZZa 
within phagolysomes. Only a few internalized bacteria 
are capable of avoiding lysosome fusion and redirecting 
their trafficking to their final place of reproduction, the 
endoplasmic reticulum.28,29 
BruceZZa genomic analysis studies indicate that it has 
two chromosomes and that no plasmids are present. The 
genome contains three rRNA operons. Two are on 
chromosome I, and the third is on chromosome II. A set 
of 12 open reading frames (ORFs) located on chromo- 
some II code for a type IV secretion system. In the 
biogenesis of BruceZZu in cells, the VirB operon coding 
for the BruceZZa type IV secretion system is required 
for regulation of intracellular trafficking from 
autophagosome-like compartments to the endoplasmic 
reticulum. The integrity of the lipopolysaccharide (LPS) 
molecule on the bacterial surface is also one of the 
required factors for intracellular survival, and then for 
virulence.33v34 
During BruceZZa infection, several cytokines, such as 
interferon-gamma (IFN-y), tumor necrosis factor-alpha 
(TNF-a), interleukin-2 (IL-2), IL-10 and IL-12, control 
the intracellular growth of BruceZZa strains within 
macrophages.28 
The LPS of smooth strains probably plays a major 
role in intracellular survival. When the biological activity 
of S-LPS is compared with that of E. coli LPS, S-LPS 
has low toxicity for endotoxin-sensitive mice, rabbits 
and chick embryos, low toxicity for macrophages, low 
pyrogenity; and low hypoferremia-inducing activity. 
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It is also a weak inducer of IFN, TNF, nitric oxide, 
cyclooxygenase-2, and the chemokine monocyte chemo- 
atractant protein-1.1,35-37 
In humans, Brucellu spp. infection results in the 
formation of granulomas consisting of epithelioid cells, 
polymorphonuclear leukocytes, lymphocytes, and some 
giant cells. The granulomatous response is characteristic 
of B. abortus infections. In B. melitensis infections, the 
granulomata are very small, but there is often toxemia. 
B. suis infection is often accompanied by chronic abscess 
formation in joints and the spleen.6z7T26,27 
An infection with Brucella spp. induces both 
humoral and cellular immunity. Although humoral 
antibodies appear to play some role in resistance to 
Brucella, cell-mediated immunity appears to be the 
principal mechanism of recovery. The serum antibody 
response to Bruce& infection in humans is character- 
ized by an initial rise in antibody titers of the IgM class, 
followed in several weeks by a predominance of IgG 
antibodies. After treatment, titers gradually come down, 
with a faster decrease of IgG antibodies than of IgM 
antibodies. In some cases, low titers of IgM antibodies 
may persist for months or years in the absence of an 
active infection.6J6,27,38 
CLINICAL MANIFESTATIONS 
Brucellosis is a systemic disease in which any organ or 
body system can be involved. The incubation period 
varies between 1 and 5 weeks, and Brucella infection 
may be asymptomatic or symptomatic. The onset of 
symptoms is acute or insidious. According to the length 
and severity of symptoms, the disease is arbitrarily 
classified as acute (less than 8 weeks), subacute (from 8 
to 52 weeks), or chronic (more than 1 year). Any organ 
involvement is often referred to as localized disease. 
It can be seen as a complication of acute brucellosis 
or may be the only manifestation of chronic 
brucellosis.6,7,27’39 
The symptoms of brucellosis are nonspecific. The 
majority of patients complain of fever, sweats, malaise, 
anorexia, headache, arthralgia, and back-ache.5-7J4,27,39 
Nowadays, in developing countries, the clinical picture 
has changed, because patients with fever generally take 
an antibiotic on their own initiative, or at the suggestion 
of the pharmacist. This has lowered the rate of positive 
blood culture, and led to difficulties in the diagnosis of 
brucellosis. In our clinic between 1989 and 1998, 
brucellosis was diagnosed in 480 patients, of whom 
67.1% had the acute form, 25.2% had the subacute 
form, 5% had the chronic form, and 2.7% were 
asymptomatic. The symptoms and findings are shown in 
Table 2.14 
Subclinical or asymptomatic infection 
This clinical form is diagnosed by positive serology. The 
patients have no history or physical signs of acute or 
Table 2. Symptoms and clinical findings in 480 patients 
No. of patients % 
Symptoms 
Malaise 432 90 
Sweating 405 84.4 
Arthralgia 393 81.9 
Fever 383 79.8 
Back pain 281 58.5 
Myalgia 236 49.2 
Weight loss 213 44.4 
Anorexia 198 41.3 
Nausea 155 32.3 
Vomiting 104 21.7 
Abdominal pain 101 21 
Headache 91 19 
Findings 
Fever 187 39 
Hepatomegaly 102 21.3 
Osteoarticular involvementa 91 19 
Splenomegaly 68 14.2 
Neurological involvementb 31 6.5 
Genitourinary involvementC 5 1 
Endocarditisd 2 0.4 
Peritonitis 2 0.4 
Cutaneous involvement 2 0.4 
Pneumonia 1 0.2 
a Neurologic involvement in two patients. 
!‘Multisystem involvement (acute respiratory distress syndrome due to 
pneumonia, meningitis, hepatitis, hematopoetic and cutaneous 
endocarditis) in one patient and osteoarticular involvement in two 
patients 
‘Epididymo-orchitis in four patients, prostatitis in one patient 
dMultisystem involvement in one patient 
chronic illness. It has been documented more frequently 
in farmers, abattoir workers, and veterinarians.6,39 
Acute form 
This is the typical form of brucellosis. Almost all patients 
have a history of fever accompanied by weakness, 
malaise, headache, back-ache, anorexia, weight loss, 
myalgia, and arthralgia. A temperature over 38.5”C is 
measured in more than 85% of patients. Splenomegaly 
and hepatomegaly are found in about 6-35% of the 
cases.5,6J4,27,40-46 Any organ involvement can be seen, 
but arthritis is more frequent (40-50%).5,40d6 
Subacute form 
This refers to a group of patients who have relapsed 
because of incomplete or partial antibiotic treatment and 
patients who have received inappropriate antibiotics 
because of incorrect diagnosis. The clinical picture is 
more protean and may be an important cause of fever 
of unknown origin. The symptoms are generally milder, 
and localized infection can be seen.6J4 
Chronic form 
Chronic brucellosis is similar to chronic fatigue 
syndrome. It is extremely rare in children, but frequent 
in older people. These patients generally suffer from a 
psychoneurosis, sweating, and weight loss. Fever is rare. 
Localized infection can be seen; however, ocular 
manifestations, such as episcleritis and uveitis, are 
frequent.6,39 
Localized infection 
Localized brucellosis refers to cases in which organisms 
are not isolated from blood but are localized in specific 
tissues, such as the bone, joints, cerebrospinal fluid, liver, 
kidneys, spleen, or skin. Localization may be the 
principal manifestation of systemic infection, or may be 
the only manifestation of a chronic infection. Localized 
infection is sometimes named as a complication when it 
occurs as a result of systemic infection.6,27,39 In our 
series, 133 (27.7%) of 480 patients had complications. In 
this study, we accepted any organ involvement as a 
complication of brucellosis.14 The identification of any 
organ involvement is very important for the choice of 
regimen and its duration, and the prognosis. 
Skeletal system 
Osteoarticular complications are common in brucellosis, 
and clinical manifestations include arthralgias, arthritis, 
spondylitis, sacroiliitis, osteomyelitis, tenosynovitis, and 
bursitis. Arthralgia can present in up to 85 % of patients 
with brucellosis.6J1,41-3 Many studies have reported the 
clinical manifestations of osteoarticular infection in 
17-37% in patients. B. melitensis is responsible for 
almost all cases of osteoarticular involvement.6J4,41-5 
The sites of osteoarticular involvement obtained from 
some selected studies are shown in Table 3. The most 
commonly affected sites are the sacroiliac joints.14,40-42 
Spondylitis is one of the most serious complications 
of brucellosis. It is reported at a rate of 2-58% in patients 
with brucellosis. This complication is usually seen in 
elderly patients, and affects the lumbar vertebrae. Back or 
neck pain, fever and constitutional symptoms are the 
most common symptoms. Paravertebral abscesses, spinal 
epidural abscesses and neurologic complications can be 
seen with the extension of infection (Figure 2).40,4U7 
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Nervous system 
Nervous system involvement is seen in about 2-6.5% of 
brucellosis cases. Neurologic complications may occur at 
any stage of the disease. Clinical syndromes include 
meningitis, encephalitis, meningoencephalitis, radiculitis, 
myelitis, and neuritis. 14J6,27,4a-50 In our series, nervous 
system involvement was observed in 31 (6.5%) of 480 
patients with brucellosis, of whom 17 (54.8%) had 
meningitis, 4 (12.9%) encephalitis, 2 (6.5%) myelitis, 1 
(3.2%) meningoencephalitis, 1 (3.2%) meningomyelitis, 
1 (3.2%) polyradiculoneuritis, 2 (6.5%) peripheral 
neuritis, 2 (6.5 %) meningitis plus peripheral neuritis, and 
1 (3.2 %) cerebral infarct.14 
Meningitis is the most frequent central nervous 
system complication, clinically presenting as a subacute 
or chronic disease. Cerebrospinal fluid analysis reveals 
a lymphocytic pleocytosis, elevated protein, and low 
glucose levels.48-50 
Cardiovascular system 
Endocarditis is the most serious clinical form, and may 
lead to death; however, it occurs in less than 2% of cases. 
The clinical presentation is similar to that of other 
bacterial endocarditis, except that there are difficulties 
in the isolation of Brucella from blood cultures. The 
aortic valve or mitral valve is generally infected.26J7,51-53 
Myocarditis, pericarditis and infected aortic aneurisms 
have been noted.26,27 Multisystem involvement, 
including meningitis, pneumonia, hepatitis, skin lesions, 
nephritis, and peritonitis with endocarditis, have been 
reported.53,54 
Gastrointestinal system 
Gastrointestinal system symptoms, including anorexia, 
nausea, vomiting, diarrhea, abdominal pain, and gastro- 
intestinal bleeding, can be seen in brucellosis.6J4,26,27,55,56 
Liver and spleen enlargement with mild nonspecific 
elevation of liver enzyme levels can be detected in 
approximately 50% of patients with brucellosis. How- 
ever, diffuse hepatitis or granulomatous hepatitis is also 
Table 3. Anatomic distribution of osteoarticular involvement of brucellosis in selected studies (%). 
Site Colmenero et aL40 Mousa et aL4’ 
n=65 n=169 
Tasova et aI.@ 
n=87 
Aygen et a1.l4 
n=91 
Sacroiliitis 45 20 60.9 53.8 
Spondylitis 58 6 13.8 9.9 
Knee 2 36 8 26.3 
Hip 3 53 - 
Ankle 6 15 5.7 2.1 
Elbow 5.3 
Shoulder 5 1 
Wrist 3.5 
Sternoclavicular 2 1.8 
Foot interphalangial 1 
Bursitis 3 1.2 5.7 2.2 
Polyarthricular 22 Not stated 5.7 2.1 
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Figure 2. Psoas and epidural abscesses secondary to brucellar spondylitis. (A) The saggital T1-weighted image revealing an epidural 
abscess and involvement of the body of L3. (B) An axial Tr-weighted image revealing a left paravertebral abscess at L3. 
seen during the course of brucellosis.26,27,57-59 Abscesses 
in liver and spleen57,58 and spontaneous peritonitis in 
cirrhotic patients l&l7 have also been reported as rare 
complications of brucellosis. 
Hematopoietic system 
Hematologic abnormalities, such as anemia, leuko- 
penia, and thrombocytopenia, are common in the 
course of brucellosis. Leukopenia with lymphocytosis is 
characteristic of brucellosis.14J7,41,55,56 In our series, 
anemia was found in 54.6% of the cases, leukocytosis 
in 6.5%) leukopenia in 7.7 %, lymphopenia in 63 %, and 
thrombocytopenia in 13.7%.14 Petechial or purpuric 
skin and mucosal lesions, epistaxis, hemoptysis and 
gastrointestinal or vaginal bleeding can be seen, and 
these complications are significantly associated with 
clotting abnormalities (low platelet count, low 
fibrinogen level, and prolongation of thrombin clotting 
time).27,56,60 Occasionally, thrombocytopenia may be 
severe enough to cause bleeding and result in death. 
Forty-three cases of brucellosis complicated by 
thrombocytopenic purpura, with a mortality rate of 
9.3%, have been reported in the world literature. 
Possible mechanisms for thrombocytopenia are hyper- 
splenism, reactive hemophagocytosis, and immune 
destruction of platelets.60 
Genitourinary system 
Genitourinary involvement occurs in l-20% of patients 
with brucellosis. Unilateral epididymo-orchitis is the 
usual manifestation. Pyelonephritis, interstitial nephritis, 
renal abscess, cystitis and prostatitis are rare complic- 
ations. The onset of symptoms is generally acute (78%) 
and less frequently (22%) subacute or chronic. The 
clinical presentation includes genitourinary symptoms 
and systemic symptoms.61”4 
In pregnant animals, Brucella organisms preferenti- 
ally reproduce in placental trophoblasts during the 
middle and late stages of gestation. Infected tropho- 
blasts produce cortisol, which is not normally generated 
by the placenta. Erythritol is a key sugar produced by 
the pregnant host, and Brucella can utilize it. Erythritol 
is not present in human placenta.28,33 BruceZZa can infect 
human chorioamniotic tissue during pregnancy, and 
brucellosis can cause abortion, premature delivery, and 
intrauterine infection with fetal death. It is well known 
that the effect of BruceZZa infection on pregnancy is 
no more than those of other bacterial infections.27,39 
However, a retrospective study from Saudi Arabia 
reported that the incidence of spontaneous abortion in 
the first and second trimesters was 43%, and that of 
intrauterine fetal death in the third trimester was 2%.65 
This result needs to be evaluated with a prospective and 
controlled clinical study. 
Other systems 
A variety of skin lesions have been described in brucel- 
losis, including maculopapular lesions, papules, petechiae, 
purpura, impetiginous and psoriform lesions,@+j7 ocular 
lesions; uveitis, choroiditis and scleritis,26,27 respiratory 
system involvement, pneumonia, acute respiratory 
distress syndrome, empyema, and mediastinitis.54@,69 
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Diagnosis 
The diagnosis of brucellosis requires the isolation of 
Brucella from blood or body tissues, or the combination 
of suggestive clinical presentation and positive serology. 
A definitive diagnosis of brucellosis is based on the 
culture of Brucella from different samples, mainly blood. 
In the case of focal complications, culture material, if 
possible, should be taken from the affected places, such 
as liver, lymph node, abscess, synovial fluid, prostatic 
fluid, or cerebrospinal fluid.3,s,6~26J7 The bacteria grow 
slowly in vitro, and most blood cultures are positive 
between the 7th and 21st day using classic biphasic 
Castaneda flasks. The rate of positive blood cultures in 
brucellosis ranges from 15% to 80%.3,5%6J4,70 The 
number of positive results is usually greater in acute 
brucellosis; however, this figure is notably reduced in the 
case of focal complications and chronic illness. In our 
study, positive blood cultures were detected in 45% of 
the patients with brucellosis.14 Currently, automated 
blood culture systems (BacT/Alert, BACTEC 9000 
series, Vital, ESP) have replaced conventional blood 
culture systems in many laboratories. Automated blood 
culture systems seem to shorten the time (mean time 
3 days) needed to detect these organisms from blood 
and other body fluids.3-6 
A study showed that bone marrow cultures were 
significantly more sensitive than cultures of blood (92% 
versus 70%, respectively), and the time to detection was 
shorter for bone marrow cultures than for blood 
cultures.70 Bone marrow culture is recommended for 
patients with fever of unknown origin, negative serology, 
unexplained hematologic involvement, and suspicion of 
chronic brucellosis. 
Amplification of DNA by polymerase chain reaction 
(PCR) is currently used to diagnose brucellosis. For PCR, 
peripheral blood or non-blood samples can be used.71z72 
It was reported that the sensitivity of PCR was 100% and 
the specificity 98.3% in patients with brucellosis of 
bacteremic, non-bacteremic and focal complications.71 
PCR appears to be a very useful technique for the initial 
diagnosis and the early detection of relapses.73 However, 
it is not yet routinely used. 
In the absence of bacterial isolation, the diagnosis 
can be made serologically. Several serologic tests have 
been developed to measure antibodies against bru- 
cellae: the tube agglutination test (TAT), the rose 
Bengal test, the anti-Brucella Coombs test, and ELISA. 
The TAT is widely used, and a single titer of 2160 or 
a fourfold rise in titer is considered significant.3,38,74 
A modification of the assay involving the use of 2- 
mercaptoethanol allows the measurement of only IgG. 
After cure, the IgG may be present for as long as 
1 year, and the titer may increase in patients who 
relapse.3,38 Detection of antibodies to Brucella cyto- 
plasmic proteins by ELISA and Western blot in 
cerebrospinal fluid is another diagnostic approach in 
neurobrucellosis.75 
A serologic cross-reaction can be seen between 
Brucella infection and Yersinia enterocolitica 0:9 infec- 
tion. The S-LPS of smooth Brucella spp. contain two 
distinct epitopes, designated A and M. The A-epitope is 
identical to the already mentioned a-1,2-linked polymers 
of the pentasaccharide N-acetyl-6amino-4,6-dideoxy-a- 
D-mannose, and comprises four or five sugar units. This 
epitope is present in Yersinia enterocolitica 0:9 and in 
Brucella spp., which explain this serologic cross- 
reactivity. The M-epitope seems to be specific for 
Brucella strains?6 
Treatment 
Appropriate antibiotics should have in vitro activity 
and adequate intracellular concentrations. Previous 
in vitro studies have shown that tetracycline, doxy- 
cycline, rifampicin, streptomycin and trimethoprim- 
sulfamethoxazole are active against B. melitensis.3,26,27 In 
our study including 52 isolates of B. melitensis, all the 
isolates were susceptible to tetracycline, doxycycline, 
streptomycin, rifampicin, ceftriaxone, ceftizoxime, 
ciprofloxacin, and ofloxacin, but 15 isolates were 
inhibited at high concentrations of trimethoprim- 
sulfamethoxazole (MICgo 4/76 mg/L). Erythromycin did 
not show good activity in vitro (MICgo 32 mg/L).77 
Brucella species are extremely sensitive to many anti- 
microbials; however, the results of in vitro susceptibilty 
tests do not always predict clinical efficacy. Successful 
treatment of brucellosis requires prolonged chemo- 
therapy with a combination of agents. Currently, mono- 
therapy is unacceptable. The duration of therapy should 
be individualized according to any organ involvement, 
particularly nervous system, cardiovascular system and 
osteoarticular involvement. 
The tetracyclines are, at present, the antibiotics of 
choice in brucellosis. A combination of doxycycline 
(100 mg twice daily for 6 weeks) and streptomycin 
(1 g/day for 2 weeks) has been used widely and success- 
fully, with an associated relapse rate of 5%.11J3,26,27,39 
Combinations of gentamicin or netilmicin with doxy- 
cycline have also proven to be effective, and could cause 
fewer adverse reactions.78,79 
Previously, the WHO suggested a combination of 
500 mg of oral tetracycline four times per day for 6 
weeks and intramuscular streptomycin at a daily dose 
of 1 g for the first 3 weeks. The current suggestion of the 
WHO is the combination of doxycycline (200 mg daily) 
and rifampicin (600-900 mg daily) for 6 weeks.*O 
Recently, Solera et a1,13 in a large multicenter study 
of 194 patients, showed better results with doxycycline- 
streptomycin than with the doxycycline-rifampicin 
combination (7% versus 24% of failures, P c: 0.01). The 
doxycycline-streptomycin regimen could prove to be 
more effective than the doxycycline-rifampicin regimen 
in patients with spondylitis.ll Various regimens were 
given to 480 patients with brucellosis in our study, and 
26 of these (5.4%) relapsed. One hundred and twenty- 
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five patients with no osteoarticular or nervous system 
involvement were given a combination of doxycycline 
and rifampicin. No therapeutic failure was observed, and 
relapse was determined in three (2.4%) patients in this 
group. The relapse rate- in patients with osteoarticular 
involvement (12.1%) was higher than that in other 
patient groups (4.2%).14 
Quinolones, especially ofloxacin and ciprofloxacin, 
have good activity in vitro. 77 Monotherapy with quino- 
lones is unacceptable, as the relapse rate is over 21 %.sl 
In a small comparative clinical study, the ofloxacin- 
rifampicin combination was as effective as the 
doxycycline-rifampicin combination given over a 6- 
week period.i2 
Although brucellae are moderately sensitive to 
trimethoprim-sulfamethoxazole. It can be used as an 
alternative, particularly in children and pregnant 
women.26,27,65 Azithromycin has also shown in vitro 
activity against Brucella, but a clinical trial with an 
azithromycin-gentamicin combination showed a high 
rate of therapeutic failure and relapse.82 
The therapy for any organ involvement or complic- 
ations is the same as for brucellosis without focal 
disease. A few localized forms may require surgery. 
Mortality due to Brucella endocarditis has been reduced 
significantly by a medical-surgical approach to treat- 
ment.51 The duration of therapy must be individualized. 
In cases of osteoarticular involvement, particularly 
spondylitis, the duration of therapy should be at least 
8 weeks (8-12 weeks).6J4,41,43”7 
The preferred regimen in neurobrucellosis is a 
combination of doxycycline and rifampicin. Our initial 
suggestion is the addition of a third-generation cephalo- 
sporin (ceftriaxone for 2-3 weeks) to the combination. 
In our clinical study, in 24 cases with neurobrucellosis, no 
therapeutic failure or relapse were observed with the 
combination doxycyline-rifampicin-ceftriaxone. The 
duration of therapy in neurobrucellosis should be 
8-12 weeks or longer.14%48 
All regimens currently used have abated symptoms 
and reduced complications, but therapeutic failure or 
relapse has been seen. Those patients may require a 
second cure. Mortality is low in brucellosis. Three deaths 
(0.6%) (two due to neurobrucellosis, and one due to 
endocarditis) were seen among our cases.14 
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